Solid Biosciences Inc. Common Stock SLDB
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T07:29:10.706Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:00.662413973Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T07:29:08.453815+00:00
Solid Biosciences Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | 7.06 | 228.5% | 26.6% | |||
| 45Δ | 7.34 | 206.7% | 22.4% | |||
| 50Δ | 7.62 | 184.9% | 18.1% | |||
| 55Δ | 7.91 | 163.2% | 13.8% | |||
| 60Δ | 8.18 | 148.6% | 11.0% | |||
| 65Δ | 7.39 | 300.1% | 53.4% | 8.44 | 137.7% | 8.8% |
| 70Δ | 6.14 | 281.1% | 36.4% | 8.70 | 126.7% | 6.6% |
| 75Δ | 5.45 | 244.9% | 26.4% | 8.96 | 115.8% | 4.4% |
| 80Δ | 4.83 | 206.7% | 17.3% | 10.20 | 128.1% | 3.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.06
- IV
- 228.5%
- B/E move
- 26.6%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.34
- IV
- 206.7%
- B/E move
- 22.4%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.62
- IV
- 184.9%
- B/E move
- 18.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.91
- IV
- 163.2%
- B/E move
- 13.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.18
- IV
- 148.6%
- B/E move
- 11.0%
65Δ
- Pseudo strike
- 7.39
- IV
- 300.1%
- B/E move
- 53.4%
- Pseudo strike
- 8.44
- IV
- 137.7%
- B/E move
- 8.8%
70Δ
- Pseudo strike
- 6.14
- IV
- 281.1%
- B/E move
- 36.4%
- Pseudo strike
- 8.70
- IV
- 126.7%
- B/E move
- 6.6%
75Δ
- Pseudo strike
- 5.45
- IV
- 244.9%
- B/E move
- 26.4%
- Pseudo strike
- 8.96
- IV
- 115.8%
- B/E move
- 4.4%
80Δ
- Pseudo strike
- 4.83
- IV
- 206.7%
- B/E move
- 17.3%
- Pseudo strike
- 10.20
- IV
- 128.1%
- B/E move
- 3.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 188.98% | |
| 179.68% | |
| 203.73% | |
| 224.60% | |
| 196.97% | |
| 142.16% | |
| 213.61% | |
| 214.88% | |
| 243.67% | |
| 249.99% |
Biotechnology
SLN
Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other…
More →SLS
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the…
More →SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The…
More →SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
More →SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR)…
More →SPRY
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to…
More →